Indegene

Indegene achieved significant milestones in Q4 FY26, with revenues exceeding ₹1,000 crores (₹10,000 million) for the first time, representing a 32.8% YoY and 6.5% QoQ growth. For the full fiscal year, revenues crossed ₹3,500 crores (₹35,105 million), growing 23.6% in INR and 18.2% in USD terms. Adjusted EBITDA for Q4 stood at ₹1,889 million (up 23.2% YoY) and for FY26 at ₹6,793 million (up 20.8% YoY). Despite these strong operational results, reported PAT for FY26 declined 1.4% to ₹4,011 million, primarily due to a ₹241 million charge from currency volatility and a ₹203 million provision for a legal settlement.

The company demonstrated robust customer growth and deepening relationships in FY26. The total active customer base expanded from 73 to 91, while the number of customers contributing over $1 million in annual revenue increased by approximately 30%, from 41 to 53. This growth in the mid-tier cohort outpaced the top 20, validating Indegene's 'land and expand' model. Management highlighted that this diversification ensures the business is not top-heavy and builds a durable portfolio, with several newer relationships already scaling to $5 million ACV engagements.

Indegene emphasized its decade-long investment in AI, which is now yielding significant wins and driving productivity, with revenue per employee reaching $75,000 per annum, up from $56,000 three years prior. Key GenAI-powered solutions include an omnichannel orchestration deal with a top 5 customer, end-to-end commercialization for a mid-sized biotech, and AI-driven pharmacovigilance. The company differentiates itself through deep domain knowledge, proprietary data, and agentic human-in-the-loop workflows, which are critical in the highly regulated life sciences sector where LLMs alone are insufficient.

In FY26, Indegene completed three strategic acquisitions: BioPharm, Warn Communications, and Cake Communications, with total outflows of ₹7,253 million for acquisitions during the year. BioPharm strengthened omnichannel data capabilities, while Warn and Cake enhanced European market presence and expertise. These acquisitions, along with initiatives like 'Tectonic' (GenAI with creative expertise), are positioning Indegene as a strategic operating partner for life sciences, taking share from traditional agencies and CROs, and expanding its addressable market through AI-led operating models.

Management expressed confidence for FY27, citing a stronger and higher pipeline across both top 20 and outside top 20 customers. Key growth drivers include the scaling of GenAI-led solutions, the Tectonic model, and the conversion of strategic deals into revenue, such as a multiyear omnichannel deal expected to convert in H2 FY27. The company anticipates improved profitability and EBITDA margins in FY27, with PAT seeing significant upward movement as one-time^📎 impacts fade and amortization stabilizes. The pharma industry is projected to grow at a healthy 5-8% CAGR from 2026-2028, providing a favorable backdrop.